Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E - PubMed (original) (raw)
. 1996 Mar 21;334(12):752-8.
doi: 10.1056/NEJM199603213341202.
Affiliations
- PMID: 8592548
- DOI: 10.1056/NEJM199603213341202
Free article
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E
E M Reiman et al. N Engl J Med. 1996.
Free article
Abstract
Background: Variants of the apolipoprotein E allele appear to account for most cases of late-onset Alzheimer's disease, and persons with two copies of the epsilon 4 allele appear to have an especially high risk of dementia. Positron-emission tomography (PET) has identified specific regions of the brain in which the rate of glucose metabolism declines progressively in patients with probable Alzheimer's disease. We used PET to investigate whether these same regions of the brain are affected in subjects homozygous for the epsilon 4 allele before the onset of cognitive impairment.
Methods: Apolipoprotein E genotypes were established in 235 volunteers 50 to 65 years of age who reported a family history of probable Alzheimer's disease. Neurologic and psychiatric evaluations, a battery of neuropsychological tests, magnetic resonance imaging, and PET were performed in 11 epsilon 4 homozygotes and 22 controls without the epsilon 4 allele who were matched for sex, age, and level of education. An automated method was used to generate an aggregate surface-projection map that compared regional rates of glucose metabolism in the two groups.
Results: The epsilon 4 homozygotes were cognitively normal. They had significantly reduced rates of glucose metabolism in the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease. They also had reduced rates of glucose metabolism in additional prefrontal regions, which may be preferentially affected during normal aging.
Conclusions: In late middle age, cognitively normal subjects who are homozygous for the epsilon 4 allele for apolipoprotein E have reduced glucose metabolism in the same regions of the brain as in patients with probable Alzheimer's disease. These findings provide preclinical evidence that the presence of the epsilon 4 allele is a risk factor for Alzheimer's disease. PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease.
Comment in
- Second cancers after Hodgkin's disease in childhood.
Donaldson SS, Hancock SL. Donaldson SS, et al. N Engl J Med. 1996 Mar 21;334(12):792-4. doi: 10.1056/NEJM199603213341210. N Engl J Med. 1996. PMID: 8592556 No abstract available. - Positron-emission tomography and Alzheimer's disease.
Pedro-Botet J, Rubiés-Part J. Pedro-Botet J, et al. N Engl J Med. 1996 Jul 18;335(3):207-8. N Engl J Med. 1996. PMID: 8657229 No abstract available.
Similar articles
- Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.
Reiman EM, Chen K, Alexander GE, Caselli RJ, Bandy D, Osborne D, Saunders AM, Hardy J. Reiman EM, et al. Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9. doi: 10.1073/pnas.2635903100. Epub 2003 Dec 19. Proc Natl Acad Sci U S A. 2004. PMID: 14688411 Free PMC article. - Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.
Reiman EM, Caselli RJ, Chen K, Alexander GE, Bandy D, Frost J. Reiman EM, et al. Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9. doi: 10.1073/pnas.061509598. Proc Natl Acad Sci U S A. 2001. PMID: 11248079 Free PMC article. - Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.
Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L, et al. Small GW, et al. JAMA. 1995 Mar 22-29;273(12):942-7. JAMA. 1995. PMID: 7884953 - Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.
Small GW. Small GW. J Clin Psychiatry. 1996;57 Suppl 14:9-13. J Clin Psychiatry. 1996. PMID: 9024331 Review. - Early detection of Alzheimer's disease using neuroimaging.
Mosconi L, Brys M, Glodzik-Sobanska L, De Santi S, Rusinek H, de Leon MJ. Mosconi L, et al. Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. doi: 10.1016/j.exger.2006.05.016. Epub 2006 Jul 12. Exp Gerontol. 2007. PMID: 16839732 Review.
Cited by
- Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.
Randall C, Mosconi L, de Leon M, Glodzik L. Randall C, et al. Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170. Front Biosci (Landmark Ed). 2013. PMID: 23747874 Free PMC article. Review. - Coevolution of brain structures in amnestic mild cognitive impairment.
Carmichael O, McLaren DG, Tommet D, Mungas D, Jones RN; Alzheimer's Disease Neuroimaging Initiative. Carmichael O, et al. Neuroimage. 2013 Feb 1;66:449-56. doi: 10.1016/j.neuroimage.2012.10.029. Epub 2012 Oct 24. Neuroimage. 2013. PMID: 23103689 Free PMC article. - An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease.
Jack CR Jr, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC. Jack CR Jr, et al. Ann Neurol. 2012 Jun;71(6):765-75. doi: 10.1002/ana.22628. Epub 2012 Apr 9. Ann Neurol. 2012. PMID: 22488240 Free PMC article. - Event-related functional magnetic resonance imaging changes during relational retrieval in normal aging and amnestic mild cognitive impairment.
Giovanello KS, De Brigard F, Hennessey Ford J, Kaufer DI, Burke JR, Browndyke JN, Welsh-Bohmer KA. Giovanello KS, et al. J Int Neuropsychol Soc. 2012 Sep;18(5):886-97. doi: 10.1017/S1355617712000689. Epub 2012 May 24. J Int Neuropsychol Soc. 2012. PMID: 22622022 Free PMC article. - Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes.
Riviere ME, Langbaum JB, Turner RS, Rinne JO, Sui Y, Cazorla P, Ricart J, Meneses K, Caputo A, Tariot PN, Reiman EM, Graf A. Riviere ME, et al. Alzheimers Dement. 2024 Mar;20(3):1839-1850. doi: 10.1002/alz.13532. Epub 2023 Dec 25. Alzheimers Dement. 2024. PMID: 38145469 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical